European Journal Of Haematology · 1998 · 24 citations · 26 references
MedicineHematologyOncologyCancer ImmunologyHematologic OncologyMolecular OncologyChemotherapy In Hematologic MalignanciesHematologic MalignanciesHematologic Malignancy TherapyMinimal Residual DiseaseMyeloproliferative NeoplasmsRelapsed DiseaseChronic Lymphocytic Leukemia TherapyFludarabine-based RegimensGene Rearrangement AnalysisGenomic Rearrangement AnalysisNeoplastic DiseaseNon-hodgkin Lymphoma TreatmentPartial Response AssessmentTherapy Response Evaluation
Fludarabine (25 mg/m2 for 5 d, every 4 wk, for 6 courses) was administered as first line therapy in 32 symptomatic chronic lymphoproliferative diseases. All CLL patients achieved at least partial response (5 CR, 2 nPR, 9 PR) but 44% of patients relapsed. In LG-NHLs response and relapse rate were similar. Haematological toxicity was low. VDJ rearrangement PCR analysis was performed on marrow samples at diagnosis and at the time of response evaluation. In the 3 patients who underwent high dose therapy with peripheral blood progenitor cell rescue analysis was also performed on apheresis samples and on marrow samples at the end of the procedure. Clonal VDJ rearrangement was always evident after Fludarabine therapy even in those patients who achieved histological and immunophenotypic complete remission, whereas it disappeared in 2 of 3 patients who underwent HDT. Our data confirm that Fludarabine monotherapy can reduce the neoplastic mass to a subclinical level and suggest the possibility that high dose therapy might produce true complete remission.
26
Molecular cloning: A laboratory manual
Prescott L. Deininger · Analytical Biochemistry · 1990 · 86.2K citations
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Randall K. Saiki, David H. Gelfand, Susanne Stoffel et al. · Science · 1988 · 17.2K citations
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia
MJ Keating, H. Kantarjian, Moshe Talpaz et al. · Blood · 1989 · 456 citations · Full text
Medicine, Oncology, Pharmacology +9
S O'Brien, Hagop M. Kantarjian, Miloslav Beran et al. · Blood · 1993 · 280 citations · Full text
Medicine, Oncology, Pharmacotherapy +12